Legacy Private Trust Co. Abb Vie Inc. Transaction History

Legacy Private Trust Co.

$1.5 Billion
Q4 2024

A detailed history of Legacy Private Trust Co. transactions in Abb Vie Inc. stock. As of the latest transaction made, Legacy Private Trust Co. holds 25,216 shares of ABBV stock, worth $4.87 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares

25,216

Previous 24,301 3.77%

Holding current value

$4.87 Million

Previous $4.8 Million 6.63%

% of portfolio

0.3%

Previous 0.33%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 08, 2025	BUY	$164.99 - $203.87 $150,965 - $186,541	915 Added 3.77%	25,216 $4.48 Million
Q3 2024 Oct 07, 2024	BUY	$163.84 - $199.33 $617,676 - $751,474	3,770 Added 18.36%	24,301 $4.8 Million
Q2 2024 Jul 12, 2024	BUY	$154.79 - $180.76 $30,958 - $36,152	200 Added 0.98%	20,531 $3.52 Million
Q1 2024 Apr 10, 2024	SELL	$159.82 - $182.1 $98,129 - $111,809	-614 Reduced 2.93%	20,331 $3.7 Million
Q4 2023 Jan 10, 2024	SELL	$137.6 - $154.97 $15,824 - $17,821	-115 Reduced 0.55%	20,945 $3.25 Million
Q3 2023 Oct 11, 2023	SELL	$133.59 - $154.65 $96,585 - $111,811	-723 Reduced 3.32%	21,060 $3.14 Million
Q2 2023 Jul 07, 2023	BUY	$132.51 - $164.9 $44,390 - $55,241	335 Added 1.56%	21,783 $2.93 Million
Q1 2023 Apr 12, 2023	SELL	$144.61 - $166.54 $85,175 - $98,092	-589 Reduced 2.67%	21,448 $3.42 Million
Q4 2022 Jan 06, 2023	BUY	$138.31 - $165.87 $1,521 - $1,824	11 Added 0.05%	22,037 $3.56 Million
Q3 2022 Oct 06, 2022	SELL	$134.21 - $153.93 $129,378 - $148,388	-964 Reduced 4.19%	22,026 $2.96 Million
Q2 2022 Jul 07, 2022	SELL	$137.62 - $174.96 $65,644 - $83,455	-477 Reduced 2.03%	22,990 $3.52 Million
Q1 2022 Apr 11, 2022	BUY	$131.98 - $163.75 $1,319 - $1,637	10 Added 0.04%	23,467 $3.8 Million
Q4 2021 Jan 12, 2022	SELL	$107.43 - $135.93 $14,503 - $18,350	-135 Reduced 0.57%	23,457 $3.18 Million
Q3 2021 Oct 12, 2021	SELL	$106.4 - $120.78 $39,155 - $44,447	-368 Reduced 1.54%	23,592 $2.55 Million
Q2 2021 Jul 09, 2021	SELL	$105.21 - $117.21 $537,623 - $598,943	-5,110 Reduced 17.58%	23,960 $2.7 Million
Q1 2021 Apr 09, 2021	SELL	$102.3 - $112.62 $454,212 - $500,032	-4,440 Reduced 13.25%	29,070 $3.15 Million
Q4 2020 Jan 12, 2021	SELL	$80.49 - $108.67 $245,735 - $331,769	-3,053 Reduced 8.35%	33,510 $3.59 Million
Q3 2020 Oct 14, 2020	SELL	$85.91 - $100.83 $128,865 - $151,245	-1,500 Reduced 3.94%	36,563 $3.2 Million
Q2 2020 Jul 09, 2020	BUY	$73.37 - $98.18 $257,748 - $344,906	3,513 Added 10.17%	38,063 $3.74 Million
Q1 2020 Apr 23, 2020	SELL	$64.5 - $97.79 $69,337 - $105,124	-1,075 Reduced 3.02%	34,550 $2.63 Million
Q4 2019 Jan 14, 2020	SELL	$72.13 - $90.25 $216,390 - $270,750	-3,000 Reduced 7.77%	35,625 $3.15 Million
Q3 2019 Oct 10, 2019	SELL	$62.98 - $75.72 $669,036 - $804,373	-10,623 Reduced 21.57%	38,625 $2.93 Million
Q2 2019 Jul 18, 2019	SELL	$65.7 - $83.98 $145,262 - $185,679	-2,211 Reduced 4.3%	49,248 $3.58 Million
Q1 2019 Apr 11, 2019	BUY	$77.14 - $90.79 $627,919 - $739,030	8,140 Added 18.79%	51,459 $4.15 Million
Q4 2018 Jan 16, 2019	BUY	$77.85 - $96.01 $115,062 - $141,902	1,478 Added 3.53%	43,319 $3.99 Million
Q3 2018 Oct 10, 2018	BUY	$88.91 - $98.84 $815,215 - $906,263	9,169 Added 28.06%	41,841 $3.96 Million
Q2 2018 Jul 13, 2018	BUY	$89.78 - $106.23 $121,651 - $143,941	1,355 Added 4.33%	32,672 $3.03 Million
Q1 2018 Apr 13, 2018	SELL	$92.01 - $123.21 $197,361 - $264,285	-2,145 Reduced 6.41%	31,317 $2.96 Million
Q4 2017 Jan 16, 2018	SELL	$89.56 - $98.21 $39,406 - $43,212	-440 Reduced 1.3%	33,462 $3.24 Million
Q3 2017 Oct 13, 2017	BUY	$69.85 - $89.22 $2.37 Million - $3.02 Million	33,902	33,902 $3.01 Million

Others Institutions Holding ABBV

# of Institutions

3,927

Shares Held

1.26B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $341B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legacy Private Trust Co., based on Form 13F filings with the SEC.

News

Stay updated on Legacy Private Trust Co. with notifications on news.

Account

Legacy Private Trust Co. Abb Vie Inc. Transaction History